Prognostic factors in Hodgkin lymphoma

Area of Science:

• Oncology
• Hematology
• Medical Imaging

Background:

• Hodgkin lymphoma (HL) prognosis has significantly improved due to chemotherapy and risk-adapted strategies.
• Accurate risk factor identification is essential for guiding HL treatment decisions.
• Current risk stratification relies primarily on clinical factors, potentially leading to undertreatment or overtreatment.

Purpose of the Study:

• To review established clinical and biological risk factors and prognostic models for Hodgkin lymphoma.
• To discuss the role of functional imaging, specifically positron emission tomography (PET), in individualizing HL treatment.
• To summarize current standards and future perspectives in HL risk stratification.

Main Methods:

• Review of current literature on Hodgkin lymphoma prognostication.
• Analysis of established clinical risk factors and prognostic scores.
• Evaluation of biological markers and positron emission tomography (PET) in risk assessment.

Main Results:

• Clinical factors are the basis for current risk group assignments in first-line HL treatment.
• Biological factors are increasingly recognized but not yet standard in prognostication.
• Positron emission tomography (PET) is emerging as a tool for personalized therapeutic approaches.

Conclusions:

• Individualized risk stratification in Hodgkin lymphoma requires integration of clinical, biological, and imaging data.
• Further research is needed to incorporate novel prognostic factors into standard clinical practice.
• Optimizing risk assessment will enhance treatment efficacy and minimize toxicity in HL management.